Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
33.00
+7.08 (27.31%)
At close: Jun 17, 2024, 4:00 PM
33.41
+0.41 (1.24%)
Pre-market: Jun 18, 2024, 9:12 AM EDT

Mirum Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
186.3777.0619.1400
Revenue Growth (YoY)
141.85%302.66%---
Cost of Revenue
47.0412.371.900
Gross Profit
139.3464.6917.2400
Selling, General & Admin
145.8889.0759.2222.6911.75
Research & Development
102.61106.84131.4381.6142.99
Operating Expenses
248.49195.91190.65104.354.74
Operating Income
-109.15-131.22-173.41-104.3-54.74
Interest Expense / Income
15.1115.9817.590.340
Other Expense / Income
38.17-5.13-107.05-1.37-2.21
Pretax Income
-162.42-142.07-83.95-103.26-52.53
Income Tax
0.99-6.410.040.010.02
Net Income
-163.42-135.67-83.99-103.27-52.55
Shares Outstanding (Basic)
4134302511
Shares Outstanding (Diluted)
4134302511
Shares Change
20.31%12.07%20.08%119.84%-
EPS (Basic)
-4.00-4.01-2.77-4.09-4.58
EPS (Diluted)
-4.00-4.02-2.77-4.09-4.58
Free Cash Flow
-71.05-120.41-24.78-89.3-39.64
Free Cash Flow Per Share
-1.74-3.56-0.82-3.54-3.45
Gross Margin
74.76%83.94%90.06%--
Operating Margin
-58.57%-170.28%-906.12%--
Profit Margin
-87.68%-176.05%-438.85%--
Free Cash Flow Margin
-38.12%-156.26%-129.49%--
EBITDA
-135.87-122.41-65.39-102.31-52.21
EBITDA Margin
-72.90%-158.85%-341.66%--
Depreciation & Amortization
11.453.680.980.620.32
EBIT
-147.32-126.09-66.36-102.93-52.53
EBIT Margin
-79.04%-163.62%-346.75%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).